QQQ $ 623.24 $ 0.00 (0 %)
DIA $ 469.77 $ 0.00 (0 %)
SPY $ 676.00 $ 0.00 (0 %)
TLT $ 89.90 $ 0.00 (0 %)
GLD $ 367.64 $ 0.00 (0 %)
$ na
-- x --
-- x --
-- - --
na - na
0
na
na
na
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

79 clinical sites across 23 US states are currently enrolling patients in BriaCell's pivotal Phase 3 study in metastatic br...

Core News & Articles

Biomarkers identified in BriaCell's Phase 2 study are showing similar and encouraging trends in the ongoing pivotal Phase 3...

Core News & Articles

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-s...

Core News & Articles

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-s...

Core News & Articles

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-s...

Core News & Articles

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))), (TSX:BCT) ("BriaCell"), a clinical-stage biotechnology compa...

Core News & Articles

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-s...

Core News & Articles

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-s...

Core News & Articles

Sustained complete resolution of temporal lobe brain metastasis and continued orbital tumor reduction after >18 months of tr...

Core News & Articles

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-s...

Core News & Articles

Together, Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven add 30 satellite locations to enroll patients...

Core News & Articles

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ, TSX:BCT), a clinical-stage biotechnology company advancing personalized...

Core News & Articles

Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 studyBiomarkers...

Core News & Articles

(GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"),...

Core News & Articles

PHILADELPHIA and VANCOUVER, British Columbia, April 23, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTX...

Core News & Articles

BriaPro is developing novel antibodies to B7-H3, a key cancer antigen and immune checkpointHighly expressed on the cell surface...

Core News & Articles

The Data Safety Monitoring Board (DSMB) identified no safety concerns, and recommended continuation of BriaCell's pivotal P...

Core News & Articles

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage bi...

Core News & Articles

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage bi...

Core News & Articles

SABCS® "Spotlight" poster to be presented on Wednesday, December 11, 2024 7:00 AM – 8:30 AM CST highlights positive Bri...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION